Explore FDA bioequivalence standards for NTI drugs. Learn why the 90-111% limit replaces the standard 80-125% range, how quality assays are tightened to 95-105%, and which medications like warfarin and tacrolimus require these special safety protocols.
Explore the critical gaps in generic availability for combination NTI drugs. Learn about bioequivalence challenges, safety risks, and FDA regulations affecting patient care.
Combination drug substitution poses serious legal and safety challenges as current pharmacy laws struggle to keep up with complex multi-drug formulations. Patients and pharmacists face confusion, liability risks, and inconsistent rules across states.